Aardvark Adventures Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Aardvark Adventures

DAVE 207.00

-1.5%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: ~digs	9/21/2006 6:46:59 AM
	of 7944

MII 2.1 MicroIslet, Inc., a development stage biotechnology company, engages in the research, development, and commercialization of technologies in the field of transplantation therapy for patients with insulin-dependent diabetes. Its islet transplantation technology, licensed from Duke University, includes methods for isolating, culturing, cryopreservation, and immuno-protection of islet cells. The company also has collaborations with the University of Alberta for assistance in transplantation surgery and subsequent monitoring in animal models; and The Scripps Research Institute and California National Primate Research Center in the area of islet cell transplantation therapies for treatment of insulin-dependent diabetes.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next